Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
The main purpose of this research study is to evaluate the safety and dosing of CG0070.
Carcinoma, Transitional Cell|Bladder Neoplasms
BIOLOGICAL: Oncolytic adenovirus (serotype 5) - CG0070
Maximum-tolerated or maximum feasible dose in single and multidose regimens of CG0070 by intravesical administration, Study End
Assessment of the amount of CG0070 in the urine and blood over time by PCR, Study End
Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.